Systemic Interleukins' Profile in Early and Advanced Colorectal Cancer.
Paulina Czajka-FrancuzSylwia Cisoń-JurekAleksander CzajkaMaciej KozaczkaJerzy WojnarJerzy ChudekTomasz FrancuzPublished in: International journal of molecular sciences (2021)
Tumor microenvironment (TME) is characterized by mutual interactions of the tumor, stromal and immune cells. Early and advanced colorectal tumors differ in structure and present altered serum cytokine levels. Mutual crosstalk among TME infiltrating cells may shift the balance into immune suppressive or pro-inflammatory, antitumor response this way influencing patients' prognosis. Cancer-related inflammation affects all the body and this way, the systemic level of cytokines could reflect TME processes. Despite numerous studies, it is still not known how systemic cytokines levels change during colorectal cancer (CRC) tumor development. Better understanding tumor microenvironment processes could help in planning therapeutic interventions and more accurate patient prognosis. To contribute to the comprehension of these processes within TME, we reviewed cytokines levels from clinical trials in early and advanced colorectal cancer. Presented data were analyzed in the context of experimental studies and studies analyzing tumor infiltration with immune cells. The review summarizes clinical data of cytokines secreted by tumor microenvironment cells: lymphocytes T helper 1 (Th1), lymphocytes T helper 2 (Th2), lymphocytes T helper 17 (Th17), regulatory T cells (Treg cells), regulatory T cells (Breg cells), M1/M2 macrophages, N1/N2 neutrophils, myeloid-derived suppressor cells (MDSC), dendritic cells (DC), innate lymphoid cells (ILC) natural killer (NK) cells and tumor cells.
Keyphrases
- regulatory t cells
- dendritic cells
- induced apoptosis
- cell cycle arrest
- clinical trial
- peripheral blood
- randomized controlled trial
- mass spectrometry
- immune response
- end stage renal disease
- bone marrow
- big data
- ejection fraction
- open label
- pi k akt
- peritoneal dialysis
- case control
- deep learning
- patient reported outcomes
- double blind
- placebo controlled